Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-11-26
2010-11-09
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S019300, C514S119000, C514S423000, C514S626000
Reexamination Certificate
active
07829530
ABSTRACT:
One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.
REFERENCES:
patent: 4522752 (1985-06-01), Sisto et al.
patent: 5061811 (1991-10-01), Pinori et al.
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5783556 (1998-07-01), Clark et al.
patent: 5834428 (1998-11-01), Drucker et al.
patent: 5952301 (1999-09-01), Drucker et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6184201 (2001-02-01), Drucker et al.
patent: 6803357 (2004-10-01), Bachovchin et al.
patent: 6890898 (2005-05-01), Bachovchin et al.
patent: 7078381 (2006-07-01), Bachovchin et al.
patent: 7157429 (2007-01-01), Bachovchin et al.
patent: 7459428 (2008-12-01), Bachovchin et al.
patent: 19616486 (1997-10-01), None
patent: WO 89/03223 (1989-04-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 96/14857 (1996-05-01), None
patent: WO 96/39385 (1996-12-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/25644 (1998-06-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 01/14318 (2001-03-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/81337 (2001-11-01), None
J.E.F. Reynolds, “Martindale, The Extra Pharmacopoeia” 1993, The Pharmaceutical Press, London, XP002515485, pp. 281-289.
J.E.F. Reynolds (ED), “Martindale, The Extra Pharmacopoeia: Edition 31” London, The Royal Pharaceutical Society, GB, vol. ED. 31, Jan. 1, 1995, p. 357 XP002141210.
R.A. Jackson, “Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes”, Diabetes 36: 632-640 (1987).
European Search Report for EP Application No. 04029691, dated May 27, 2009.
Balkan et al., “Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese Zucker rats,” Diabetologia Suppl. 40, A131 Abstract (1997).
Bell et al., “Exon duplication and divergence in the human preproglucagon gene,” Nature 304 (5924):368-71 (1983).
Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302(5910):716-8 (1983).
Conlon, J.M., “Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles,” Diabetolgia 31(8):563-6 (1988).
Coruzzi et al., “Gastric antisecretory activity of telenzepine, a new MI-selective muscarinic antagonist: com-parison with pirenzepine,” Arch Int Pharmacodyn Ther 302:232-41 (1989).
Coutts et al., “Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV I. Variation of the P2 Position of Xaa-boroPro Dipeptides,” J. Med. Chem. 39: 2087-2094 (1996).
Deacon et al., “Both subcutaneously and intrave-nously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects,” Diabetes 44(9):1126-31 (1995).
Deacon et al., “Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig,” Diabetes, vol. 47:764-769 (1998).
Deacon et al., “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo,” J. Clin. Endocrin. 83: 952-957 (1995).
Dupre, “Influences of the gut on the endocrine pan-creas,” The Endocrine Pancreas (Raven Press, New York) pp. 253-281 (1991).
Ebert et al., “Gastrointestinal peptides and insulin secretion”, Diabetes Met. Rev. 3:1-26 (1987).
Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus”, N Engl JMed 326(20):1316-22 (1992).
Habener et al., “Biosyntesies of glucagon” The Endo-crine Pancreas (Raven Press, New York) pp. 53-71 (1991).
Holst, J. J. & Deacon, C.F., “Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes,” Diabetes 47:1663-1670 (1998).
Holst et al., “Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut,” FEBS Lett. 211(2):169-74 (1987).
Kawashima et al., “Pharmacological differentiation of presynaptic MI muscarinic receptors modulating acetylcho-line release from postsynaptic muscarinic receptors in guinea-pig ileum,” Gen Pharmacol 21(1):17-21 (1990).
Kieffer et al., “Degradation of Glucose-Dependent Inulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV,” Endocrin. 136, 3585-3596 (1995).
Kinder et al., “Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase,” JMed Chem 28(12):1917-25 (1985).
Kreymann et al., “Glucagon-like peptide-1 7-36: a physiological incretin in man,” Lancet 2(8571):1300-4 (1987).
Kubiak et al., “Metabolism or mouse growth hor-mone-releasing factor, mGRF(142)OH, and selected ana-logs from the bovine GRF series in mouse and bovine plasma in vitro,” Pept Res 7(3):153-61 (1994).
Lambrecht et al., “Pharmacology of hexahydro-difenidol, hexahydro-sila-difenidol and related selective muscarinic antagonists,” Trends Pharmacol Sci 10(Suppl):60 (1989).
Lund et al., “Pancreatic preproglucagon cDNA con-tains two glucagon-related coding sequences arranged in tandem,” Proc Mad Acad Sci USA 79(2):345-9 (1982).
Matteson et al., “Synthesis and properties of pinanediol ∀-amino boronic acids,” Organometallics 3:1284 (1984).
Mentlein et al., “Dipeptidyl-peptidase IV hydrolyses gastric Inhibitory polypeptide, glucagon-like peptide-1(736)amide, peptide histidine methionine and is responsible for their degradation in human serum,” Eur. J. Biochem. 214, 829-835 (1993).
Mentlein et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV,” Regulatory Peptides 49:133-144 (Dec. 10, 1993).
Mojsov et al., “Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-trans-lational processing,” JBiol Chem 261(25):11880-9 (1986).
Mojsov et al., “Insulinotropin: glucagon-like peptide 1(7-37) co-encoded in the glucagon gene is a potent stimu-lator of insulin release in the perfused rat pancreas,” J Clin Invest 79(2):616-9 (1987).
Mojsov, S., “Structural requirements for biological activ-ity of glucagon-like peptide-I,” Int J Pept Protein Res 40(3-4):333-43 (1992).
Orskov et al., “Pancreatic and intestinal processing of proglucagon in man,” Diabetologia 30(11):874-81 (1987).
Patzelt et al., “Identification and processing of proglucagon in pancreatic islets,” Nature 282(5736):260-6 (1979).
Pederson et al., “Improved Glucose Tolerance in Zucker Fatty Rats by Oral Admintration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide,” Diabetes 47, 1253-1258 (Aug. 1998).
Pospisilik, John A. et al., “Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26),” Regulatory Peptides 96:133-141 (2001).
Radhakrishna et al., “New method for direct conver-sion of amides to amines,” J Org Chem 44:1746 (1979).
Schmidt et al., “Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from iso-lated rat pancreatic Islets,” Diabetologia 28(9):704-7 (1985).
Shue et al., “Amide bond surrogates: a general syn-thetic route to trans carbon-carbon double bond isosteres,” Tetrahedron Letters 28:3225 (1987).
Stanley et al., “Repeated hypothalamic stimulation with neuropeptide Y increases dail
Bachovchin William W.
Drucker Daniel
Plaut Andrew G.
1149336 Ontario Inc.
Foley & Hoag LLP
New England Medical Center Hospitals
Russel Jeffrey E
Trustees of Tufts College
LandOfFree
Method of regulating glucose metabolism, and reagents... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of regulating glucose metabolism, and reagents..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of regulating glucose metabolism, and reagents... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182206